Lab21 to Distribute DeCode Tests in UK, Ireland | GenomeWeb
NEW YORK – (GenomeWeb News) – Lab21 said today that it will offer five of DeCode Genetics’ tests in the UK and in Ireland, and it will have the rights to offer new tests that are not yet on the market.
 
The agreement allows the Cambridge, UK-based Lab21 to offer DeCode’s tests for type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer, and glaucoma, as well as an upcoming test for the risk of estrogen-positive breast cancer and “a pipeline” of other tests DeCode has in development. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.